We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK plc (NYSE:GSK) ranks first among the 8 most undervalued healthcare stocks to buy according to analysts.

Next up are hopeful expansions for its antibody-drug conjugate Blenrep and asthma med Nucala, plus a new launch for biologic depemokimab. All five should help the company achieve its recently ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation ...

GSK plc announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications. The proposed indications are as add ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately controlled ...

(Alliance News) - GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application for depemokimab in two indications - for asthma with type 2 ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

The applications pertain to the use of depemokimab as an add-on maintenance treatment for asthma in patients 12 years and older with type 2 inflammation, and for adults with inadequately ...

The trials met their primary endpoints, demonstrating significant improvements in nasal polyp size and obstruction with twice-yearly dosing of depemokimab compared to placebo. The findings ...